Efficacy and Safety Evaluation of Azimilide Dihydrochloride in Patients With Implantable Cardioverter Defibrillators
Efficacy and Safety Evaluation of Azimilide Dihydrochloride in Patients With Implantable Cardioverter Defibrillators
Implantable cardioverter defibrillators (ICDs) have been developed to treat ventricular tachycardia or fibrillation (abnormal heart rhythms) by electrical shock or by pacing the heart. ICD therapy is established as highly effective for stopping life-threatening arrhythmias, but it does not preclude the use of anti-arrhythmic drugs for prevention and to decrease the frequency of ICD shocks.
The safety and effectiveness of oral azimilide dihydrochloride in reducing the frequency of ICD shocks has been investigated previously in a placebo-controlled study in patients with ICDs. These results need to be confirmed in this larger double-blind, placebo-controlled study with approximately 600 patients.
Inclusion criteria:
Exclusion criteria:
Worcester, Massachusetts 01655, United States
Rotterdam, Newfoundland and Labrador 3015 GD, Canada
Zwolle, Newfoundland and Labrador 8011JW, Canada
Ste-Foy, Quebec G1V-4G5, Canada
Winnepeg, R3E 0Z3, Canada
Bonn, 53105, Germany
Branderburg An Der Havel, 14770, Germany
Frankfurt, M. 60590, Germany
Heidelberg, 69115, Germany
Mannheim, 68135, Germany
Tübingen, 72076, Germany
Wuppertal, 42117, Germany
Eldhoven, 5602ZA, Netherlands